NASDAQ:CRBU • US1420381089
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CARIBOU BIOSCIENCES INC (CRBU).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-09 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-02-02 | Clear Street | Initiate | Buy |
| 2025-11-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-03 | Citigroup | Maintains | Buy -> Buy |
| 2025-04-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-07 | B of A Securities | Maintains | Buy -> Buy |
| 2024-11-26 | Citigroup | Maintains | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-07 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-07-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-16 | Truist Securities | Maintains | Buy -> Buy |
| 2024-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-12 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-11-08 | Cantor Fitzgerald | Initiate | Neutral |
| 2023-07-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-07-14 | Truist Securities | Reiterate | Buy -> Buy |
| 2023-07-11 | Truist Securities | Initiate | Buy |
| 2023-05-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-03-14 | HC Wainwright & Co. | Maintains | Buy |
| 2023-03-10 | Oppenheimer | Maintains | Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 34.477M 148.93% | 9.994M -71.01% | 11.159M 11.66% | 11.341M 1.63% | 12.581M 10.93% | 27.934M 122.03% | 114.29M 309.14% | 221.78M 94.05% | 2.391B 978.10% | 5.102B 113.38% | 8.152B 59.78% | |
| EBITDA YoY % growth | -112.534M -7.40% | -162.689M -44.57% | -132.549M 18.53% | -174.917M -31.96% | -159.627M 8.74% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -116.059M -9.08% | -166.616M -43.56% | -136.194M 18.26% | -139.343M -2.31% | -168.657M -21.04% | -197.913M -17.35% | -241.519M -22.03% | -256.306M -6.12% | 840.96M 428.11% | 2.343B 178.61% | 4.101B 75.03% | |
| Operating Margin | -336.63% | -1,667.16% | -1,220.49% | -1,228.67% | -1,340.57% | -708.50% | -211.32% | -115.57% | 35.17% | 45.92% | 50.31% | |
| EPS YoY % growth | -1.45 11.59% | -1.65 -13.79% | -1.59 3.64% | -1.37 13.80% | -1.34 2.25% | -2.16 -61.40% | -0.80 63.21% | -0.20 74.36% | N/A | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.32 24.60% | -0.35 39.33% | -0.36 -20.70% | -0.38 -36.61% |
| Revenue Q2Q % growth | 2.286M -2.85% | 2.703M 1.35% | 2.754M 25.30% | 2.805M -28.83% |
| EBITDA Q2Q % growth | -37.528M 10.11% | N/A | N/A | N/A |
| EBIT Q2Q % growth | -33.139M 22.78% | -23.043M 34.96% | -23.951M 18.53% | -37.838M -32.98% |
All data in USD
15 analysts have analysed CRBU and the average price target is 11.33 USD. This implies a price increase of 506.06% is expected in the next year compared to the current price of 1.87.
CARIBOU BIOSCIENCES INC (CRBU) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of CARIBOU BIOSCIENCES INC (CRBU) is -0.32 USD and the consensus revenue estimate is 2.29M USD.
The consensus rating for CARIBOU BIOSCIENCES INC (CRBU) is 85.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.